Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Dutch HTA Calls for Big Discount For Pfizer’s Vyndaqel

Executive Summary

ZIN, the Dutch health technology appraisal institute, has slammed the pricing of another rare disease treatment.

You may also be interested in...



Dutch HTA Body Hits Out At Bluebird’s Zynteglo Pricing

The Netherlands calls for multi-country price negotiations for gene therapy Zynteglo.

European Countries Should Join Forces To Lower Prices of Zolgensma & Kaftrio

The Dutch HTA institute is calling for hefty discounts of 50% and 75% for Novartis’s gene therapy and Vertex’s cystic fibrosis product.

No To Five, Yes To Three: NICE Decides On Funding For Drugs In England

Pfizer has been unsuccessful in its appeal against the health technology assessment body’s rejection of the rare heart disease drug, Vyndaqel. Meanwhile, Dr Falk Pharma has received the all-clear to make Jorveza (budesonide) available on the National Health Service for eosinophilic esophagitis.

Topics

UsernamePublicRestriction

Register

PS144871

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel